Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Grupo Español de Trasplante Hematopoyético y Terapia Celular

Le résumé fourni par la source

BACKGROUND: The number of elderly patients who could benefit from an allogeneic hematopoietic stem cell transplantation (allo-HSCT) is continuously increasing; however, the most appropriate way to select elderly candidates for this procedure is still a matter of debate. METHODS: We report the clinical outcomes of a group of 529 patients aged 65 y and older who received a first allo-HSCT between 2011 and 2020 and were reported to the Grupo Español de Trasplante Hematopoyético y Terapia Celular database. RESULTS: The median age was 67.2 y (range, 65-82) and 54 patients (10.2%) were 70 y and older. The 4-y cumulative incidence (CI) of nonrelapse mortality was 32.0% (95% confidence interval [CI], 28-36), CI of relapse was 29.1% (95% CI, 25-33), of overall survival was 43.4% (95% CI, 39-48), of progression-free survival was 38.9% (95% CI, 35-43), and of graft-versus-host disease (GvHD)-free, relapse-free survival was 23.7% (95% CI, 20-28). The 100-d CI of grades II-IV and III-IV acute GvHD was 34.7% (95% CI, 31-39) and 10.4% (95% CI, 8-13), respectively, and the 2-y CI of moderate-severe chronic GvHD was 21.0% (95% CI, 18-25). In the multivariate analysis, a hematopoietic cell transplantation-specific comorbidity index of ≥3 and a high/very high disease risk index were associated with worse overall survival; however, age did not influence the outcomes. CONCLUSIONS: Advanced age alone should not serve as an exclusion criterion for allo-HSCT, as the procedure can be both safe and effective in elderly patients with careful candidate selection and optimized transplant strategies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.